Get started
Author

Helene Hartvedt Grytli

Observed names: H. Grytli, H.H. Grytli, Helene Grytli, Helene H Grytli, Helene H. Grytli
ORCID: 0000-0002-0618-9153
Observed ORCID: 0000-0002-0618-9153
OpenAlex ID: A5061978274
Association Between Use of β-Blockers and Prostate Cancer–Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease
2013 · Helene Hartvedt Grytli, Morten Wang Fagerland, et al. · European Urology · 252
Use of β‐blockers is associated with prostate cancer‐specific survival in prostate cancer patients on androgen deprivation therapy
2012 · Helene Hartvedt Grytli, Morten Wang Fagerland, et al. · The Prostate · 144
β-Adrenergic Receptor Signaling in Prostate Cancer
2015 · Peder Rustøen Braadland, HÃ¥kon Ramberg, et al. · Frontiers in Oncology · 71
PDF
Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo Framework
2021 · Tjitske M. van der Zanden, Miriam G. Mooij, et al. · Clinical Pharmacology & Therapeutics · 63
PDF
PBX3 is a putative biomarker of aggressive prostate cancer
2016 · Håkon Ramberg, Helene Hartvedt Grytli, et al. · International Journal of Cancer · 49
PDF
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
2017 · Peder R Braadland, Guro Giskeødegård, et al. · British Journal of Cancer · 44
PDF
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2019 · Peder R. Braadland, Håkon Ramberg, et al. · Molecular Cancer Research · 30
PDF
Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence
2022 · Shivanthe Sivanesan, Kristin Austlid Taskén, et al. · JAMA Network Open · 23
PDF
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
2020 · Ingrid J. Guldvik, Verena Zuber, et al. · European Urology Open Science · 23
PDF
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
2015 · Peder Rustøen Braadland, Helene Hartvedt Grytli, et al. · Oncotarget · 13
PDF
Evidenzbasierte Off-label-Anwendung von Arzneimitteln bei Kindern und Jugendlichen
2022 · Christoph Male, Antje Neubert, et al. · Monatsschrift Kinderheilkunde · 10
PDF
Role of serum response factor expression in prostate cancer biochemical recurrence
2018 · Maria Prencipe, Aurelie Fabre, et al. · The Prostate · 10
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate–dependent protein kinase and prostate cancer aggressiveness
2016 · Line Victoria Moen, Håkon Ramberg, et al. · Urologic Oncology Seminars and Original Investigations · 9
Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's Letter to the Editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association Between Use of β-Blockers and Prostate Cancer–Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007
2013 · Helene Hartvedt Grytli, Morten Wang Fagerland, et al. · European Urology · 8
Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis
2025 · Malin Hagberg Thulin, Håkon Ramberg, et al. · Journal of Translational Medicine · 7
PDF
Erratum: Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
2018 · Peder R Braadland, Guro Giskeødegård, et al. · British Journal of Cancer · 2
PDF
Abstract C61: The use of beta blockers improve cancer-specific survival in prostate cancer patients receiving androgen deprivation therapy
2012 · Helene Hartvedt Grytli, Lise Lund Håheim, et al. · Cancer Research · 1
Perioperative propranolol during robotic‐assisted radical prostatectomy: A randomised, double‐blind, placebo‐controlled, pilot trial (PeP‐RALP)
2026 · Shivanthe Sivanesan, Håkon Ramberg, et al. · BJUI Compass
PDF
Total beta-blocker treatment delays development of castration resistance in prostate cancer xenograft models
2023 · M. Hagberg Thulin, H.K. Ramberg, et al. · European Urology Open Science
Data from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2023 · Peder R. Braadland, Håkon Ramberg, et al.
Supplementary Figure 6 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2023 · Peder R. Braadland, Håkon Ramberg, et al.
Supplementary Figure 4 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2023 · Peder R. Braadland, Håkon Ramberg, et al.
Supplementary Figure 7 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2023 · Peder R. Braadland, Håkon Ramberg, et al.
Supplementary Figure 3 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2023 · Peder R. Braadland, Håkon Ramberg, et al.
Supplementary Figure 5 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
2023 · Peder R. Braadland, Håkon Ramberg, et al.
Works count: 49
Citation count: 759
H-index: 10
I10-index: 12
Year
Topic
Type